<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0011010'>Chronic</z:hpo> exposure to high concentrations of <z:chebi fb="56" ids="16716">benzene</z:chebi> is associated with an increased incidence of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0004808'>Acute myelogenous leukemia</z:hpo> developing in patients treated with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> for other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> or occupationally exposed to <z:chebi fb="56" ids="16716">benzene</z:chebi> exhibit a pattern of cytogenetic aberrations predominantly involving loss of <z:hpo ids='HP_0000001'>all</z:hpo> or part of chromosomes 5 and/or 7 </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, <z:mp ids='MP_0004027'>trisomy</z:mp> 8 is observed equally in both de novo and secondary <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Studies using peripheral lymphocytes or lymphoblastoid cell lines have observed dose-dependent loss of chromosomes 5, 7, and 8 following treatment with the <z:chebi fb="56" ids="16716">benzene</z:chebi> metabolite, <z:chebi fb="1" ids="17594">hydroquinone</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The purpose of this study was to determine the dose response and specificity of <z:chebi fb="1" ids="17594">hydroquinone</z:chebi>-induced aberrations on chromosomes 5, 7, and 8 using human CD34+CD19 bone marrow cells </plain></SENT>
<SENT sid="5" pm="."><plain>MATERIALS AND METHODS: Fluorescence in situ hybridization analysis was performed on CD34+CD19- bone marrow cells using the locus-specific probes, 5q31, 5p15.2, and centromeric probes specific for human chromosomes 7 and 8 following <z:chebi fb="1" ids="17594">hydroquinone</z:chebi> exposure </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="1" ids="17594">Hydroquinone</z:chebi> exposure results in -7, selective deletion of 5q31 but not chromosome 5 and no loss or gain of chromosome 8 in human CD34+CD19- cells </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: CD34+ bone marrow cells are more susceptible and show a different pattern of cytogenetic aberrations as a result of <z:chebi fb="1" ids="17594">hydroquinone</z:chebi> exposure compared to lymphocytes </plain></SENT>
<SENT sid="8" pm="."><plain>CD34+ bone marrow cells exhibit unique susceptibility to the development of specific chromosome aberrations that have been identified as the earliest structural changes occurring in the development of secondary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
</text></document>